Treatment of acute myeloid leukemia with 20-30% bone marrow blasts

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 5, Issue 1, 2013, Pages

  Maurillo, Luca ^a   Buccisano, Francesco ^a   Principe, Maria Ilaria Del ^a   Sarlo, Chiara ^a   Caprio, Luigi Di ^a   Ditto, Concetta ^a   Giannotti, Federica ^a   Nasso, Daniela ^a   Ceresoli, Eleonora ^a   Postorino, Massimiliano ^a   Refrigeri, Marco ^a   Amadori, Sergio ^a   Venditti, Adriano ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BEXAROTENE; BORTEZOMIB; CLOFARABINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; LENALIDOMIDE; MIDOSTAURIN; MITOXANTRONE; RETINOIC ACID; SAPACITABINE; THALIDOMIDE; TIOGUANINE; TIPIFARNIB; VALPROIC ACID; VALSPODAR; VORINOSTAT; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLAST CELL; BONE MARROW BLAST; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOMONOCYTIC LEUKEMIA; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GERIATRIC PATIENT; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYELODYSPLASTIC SYNDROME; TREATMENT RESPONSE;

EID: 84887923235     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/mjhid.2013.032     Document Type: Article

References (84)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99 PMid:6952920
2. Sanz GF, Sanz MA, Vallespi T, Canizo MC, Torrabadella M, Garcia S, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989;74:39
3. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079 PMid:9058730
4. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24:983 http://dx.doi.org/10.1016/S0145-2126(00)00088-6
5. Seymour JF, Estey EH. The prognostic significance of Auer rods in myelodysplasia. Br J Haematol 1993;85:67-76. http://dx.doi.org/10.1111/j.1365-2141.1993.tb08647.x PMid:8251411
6. Seymour JF, Estey EH. The contribution of Auer rods to the classification and prognosis of myeldysplastic syndromes. Leuk Lymphoma 1995;17:79-85 http://dx.doi.org/10.3109/10428199509051706 PMid:7773165
7. Vallespi T, Sanz G, Torrabadella M, Irriguible D, Sanz MA. Auer rods in myelodysplastic syndromes (MDS): presence and significance. Blood 1990;76 (Suppl 1):330a (abstract).
8. Michels SD, Saumur J, Arthur DC, Robison LL, Brunning RD. Refractory anemia with excess of blasts in transformation: hematologic and clinical study of 52 patients. Cancer 1989;64:2340-6 http://dx.doi.org/10.1002/1097-0142(19891201)64:11<2340::AID-CNCR2820641125>3.0.CO;2-I
9. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849. PMid:10577857
10. Albitar M, Beran M, O'Brien S, Kantarjian, H, Frierich E, Keating M, Estey E: Differences between refractory anemia with excess blasts in transformation and acute myeloid leukaemia. Blood 2000; 96: 372-373. PMid:10939804
11. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302. http://dx.doi.org/10.1182/blood-2002-04-1199 PMid:12239137
12. Orazi A, Bennett JM, Germing U, Brunning RD, Bain BJ, Thiele J. Chronic myelomonocytic leukaemia. In: Swerdlow SH, Campo E, Jaffe ES, et al., editors. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. p. 76-9.
13. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavourable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003;21:256-65. http://dx.doi.org/10.1200/JCO.2003.08.005 PMid:12525517
14. Wandt H, Schakel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008;111:1855-61. http://dx.doi.org/10.1182/blood-2007-08-101162 PMid:18056840
15. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009;113:1906-8. http://dx.doi.org/10.1182/blood-2008-10-182782 PMid:19131546
16. Arber DA, Brunning RD, Orazi A, Bain BJ, Porwit A, Vardiman JW, et al. Acute myeloid leukaemia with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. fourth ed. Lyon: International Agency for Research on Cancer; 2008. p. 124-6.
17. Miesner M, Haferlach C, Bacher U et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood 2010;116:2742-51. http://dx.doi.org/10.1182/blood-2010-04-279794 PMid:20581309
18. Voso MT, D'Alo F, Greco M, Fabiani E, Criscuolo M, Migliora G, et al. Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact. 2010;184(1-2):46-9. http://dx.doi.org/10.1016/j.cbi.2009.10.013 PMid:19874806
19. Tien HF, Tang JH, Tsay W, Liu MC, Lee FY, Wang CH, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112(1):148-54. http://dx.doi.org/10.1046/j.1365-2141.2001.02496.x PMid:11167795
20. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003;17(9):1813-9. http://dx.doi.org/10.1038/sj.leu.2403054 PMid:12970781
21. Abdel-Wahab O, Figueroa ME. Interpreting new molecular genetics in myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2012:56-64.
22. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer.2012.12:599-612.
23. Hwang SS, Scott CB, Chang VT et al. Prediction of survival for advanced cancer patients by recursive partitioning analysis: Role of Karnofsky performance status, quality of life, and symptom distress. Cancer Invest 2004;22:678-687. http://dx.doi.org/10.1081/CNV-200032911 PMid:15581048
24. Klepin HD, Geiger AM, Tooze JA et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011 Oct;59(10):1837-46. http://dx.doi.org/10.1111/j.1532-5415.2011.03614.x PMid:22091497
25. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179-4187. http://dx.doi.org/10.1182/blood-2008-07-172007 PMid:19008455
26. Appelbaum F, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-3485. http://dx.doi.org/10.1182/blood-2005-09-3724 PMid:16455952 PMCid:1895766
27. Luger SM. Treating the elderly patient with acute myelogenous leukemia. Hematology Am Soc Hematol Educ Program; 2010:62-9. http://dx.doi.org/10.1182/asheducation-2010.1.62 PMid:21239772
28. Rowe JM, Closer to the truth in AML. Blood 2009 113:4129-4130; http://dx.doi.org/10.1182/blood-2008-12-192856 PMid:19406994
29. Estey E, Thall P, Beran M, et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90:2969-2977. PMid:9376577
30. Bernstein SH, Brunetto VL, Davey FR, et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: A Cancer and Leukemia Group B study. J Clin Oncol 1996; 14:2486-2494. PMid:8823327
31. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235-1248. http://dx.doi.org/10.1056/NEJMoa0901409 PMid:19776405
32. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010; 28:808-814. http://dx.doi.org/10.1200/JCO.2009.23.2652 PMid:20048183
33. Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML 14 trial. Br J Haematol 2009; 145:318-332. http://dx.doi.org/10.1111/j.1365-2141.2009.07604.x PMid:19291085
34. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled, trial of the Eastern Cooperative Oncology Group (ECOG 3999) Blood. 2010 Nov 18;116(20):4077-85. http://dx.doi.org/10.1182/blood-2010-04-277269 PMid:20716770 PMCid:2993615
35. Burnett A, Russell N, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy J Clin Oncol, 2010 [abstract 28] http://dx.doi.org/10.1200/JCO.2009.26.4242
36. Faderl S, Erba HP, Claxton DF, et al. Clofarabine produces durable remissions in older patients with AML with unfavorable prognostic factors and multiple comorbidities Blood, 2009; 114 [abstract 4155].
37. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112; 2008:1638-1645. http://dx.doi.org/10.1182/blood-2007-11-124602 PMid:18565853
38. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med; 1994 331:896-903. http://dx.doi.org/10.1056/NEJM199410063311402 PMid:8078551
39. Lowenberg B, Beck J, Graux C, et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010;115:2586-2591. http://dx.doi.org/10.1182/blood-2009-10-246470 PMid:20103782
40. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J ClinOncol 2008; 26:4934-4939. http://dx.doi.org/10.1200/JCO.2008.17.0472 PMid:18591543 PMCid:2652081
41. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood.2001;98:1302-1311. http://dx.doi.org/10.1182/blood. V98.5.1302 PMid:11520775
42. Gardin C, Turlure P, Fagot T, et al. Post remission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129-5135. http://dx.doi.org/10.1182/blood-2007-02-069666 PMid:17341661
43. Schlenk RF, Frohling S, Hartmann F, et al. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment trial. Leukemia, 2006: 20:748-750. http://dx.doi.org/10.1038/sj.leu.2404122 PMid:16437135
44. Chevallier P, Blaise D, Milpied N, et al. Reduced intensity conditioning (RIC) allogeneic stem cell transplantation for patients aged >=60 years: a retrospective study of 629 patients from the Societe Francaise De Greffe De Moelle et de therapie cellulaire (SFGM-TC) Blood 2009; 114:84-85.
45. Röllig C, Thiede C, Gramatzki M, et al. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood 2010;116:971-978. http://dx.doi.org/10.1182/blood-2010-01-267302 PMid:20442365
46. Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 2007; 109:1395-1400. http://dx.doi.org/10.1182/blood-2006-05-021907 PMid:17038533
47. Kurosawa S, Yamaguchi T, Uchida N, et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant. 2011 Mar;17(3):401-11. http://dx.doi.org/10.1016/j.bbmt.2010.07.013 PMid:20667478
48. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25:1908-1915. http://dx.doi.org/10.1200/JCO.2006.10.2731 PMid:17488990
49. Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukaemia. Blood.2010;116:4422-4429. http://dx.doi.org/10.1182/blood-2010-03-276485 PMid:20668231
50. Issa JP, Baylin SB, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications. Leukemia. 1997;11:S7-S11. PMid:9130685
51. Desmond JC, Raynaud S, Tung E, Hofmann W-K, Haferlach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia. 2007;21:1026-1034. PMid:17330099
52. Redner RL, Wang J, Liu JM. Chromatin remodeling and leukemia: new therapeutic paradigms. Blood. 1999;94:417-428. PMid:10397708
53. Will B, Zhou L, Vogler TO et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120:2076-86 http://dx.doi.org/10.1182/blood-2011-12-399683 PMid:22753872
54. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-70. http://dx.doi.org/10.1038/5947 PMid:9988266
55. Leone G, Teofili L, Voso MT et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Hematologica. 2002; 87: 1324-41
56. Santini V, Kantarjian HM, Issa J-P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001; 134 (7): 573-86 http://dx.doi.org/10.7326/0003-4819-134-7-200104030-00011 PMid:11281740
57. Silverman LR. Oncologist. 2001 6 (S5): 8-14 http://dx.doi.org/10.1634/theoncologist.6-suppl_5-8 PMid:11700387
58. Silverman LR, Holland JF, Demakos EP et al. Azacitidine (AZA C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. [abstr. 46] Ann Hematol 1994:68 (6): A12
59. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine inpatients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440. http://dx.doi.org/10.1200/JCO.2002.04.117 PMid:12011120
60. Cheson BD, Bennett JM, Kantarjian H, et al: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674, 2000 PMid:11090046
61. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.J Clin Oncol 2006;24:3895-903. http://dx.doi.org/10.1200/JCO.2005.05.4346 PMid:16921040
62. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in thetreatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32. http://dx.doi.org/10.1016/S1470-2045(09)70003-8
63. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in older adult patients with low bone marrow blast count (20-30%) acute myeloid leukemia. J Clin Oncol.2009;28:562-569. http://dx.doi.org/10.1200/JCO.2009.23.8329 PMid:20026804
64. Celgene Corporation. Study of Vidaza versus conventional care regimens for the treatment of acute myeloid leukemia (AML) [ClinicalTrials.gov identifier NCT01074047]. US National Institutes of Health, Clinical Trials.gov [online]
65. Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly(= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; 76 (3): 218-27 http://dx.doi.org/10.1016/j.critrevonc.2010.04.005 PMid:20451404
66. Thépot S, Itzykson R, Seegers V, et al. Azacytidine(AZA) as first line therapy in AML: results of the French ATU program. Blood (ASH Annual MeetingAbstracts). 2009;114:843.
67. Itzykson R, Thépot S, Recher C, et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU program. Blood (ASH Annual Meeting Abstracts).2009;114:1054.
68. Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood.2011;117:403-411 http://dx.doi.org/10.1182/blood-2010-06-289280 PMid:20940414
69. Maurillo L, Venditti A, Spagnoli A et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012 Feb 15;118 (4):1014-22 http://dx.doi.org/10.1002/cncr.26354 PMid:21761399
70. Al Ali HK, Jaekel N, Junghanss C et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012 Jan; 53 (1): 110-7 http://dx.doi.org/10.3109/10428194.2011.606382 PMid:21767242
71. Van der Helm LH, Alhan, C, Wijermans PW et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukemia (AML) patients in the Dutch azacitidine compassionate named patient programme. Br J Haematol. 2011 Dec;155(5):599-606 http://dx.doi.org/10.1111/j.1365-2141.2011.08893.x PMid:21981697
72. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302-2308. http://dx.doi.org/10.1182/blood-2007-03-078576 PMid:17596541
73. Raffoux E, Cras A, Recher C et al. Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome. Oncotarget. 2010; May; 1(1):34-42 PMid:21293051
74. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher. S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596-1604 http://dx.doi.org/10.1002/cncr.23789 PMid:18720364
75. Silverman LR, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol. 2008;26(suppl.).Abstract 7000.
76. Pollyea DA, Zehnder J, Coutre S, et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukaemia. Haematologica. 2012 Dec 14. [Epub ahead of print].
77. Grovdal M, Karimi M, Khan R et al. Manteinance treatment with azacitidine for patients with high risk myelodysplastic syndromes (MDS) or acute myeloid leukemia following MDS in complete remission after induction therapy. Br J Haematol 2010 Aug; 150 (3):293-302 http://dx.doi.org/10.1111/j.1365-2141.2010.08235.x PMid:20497178
78. Gardin C, Prébet T, Bouabdallah K, et al. A phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and high risk MDS: a GFM group study. Blood (ASH Annual Meeting Abstracts). 2009;114:844.
79. Christman JK. 5-Azacytidine and 5-aza-2-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95. http://dx.doi.org/10.1038/sj.onc.1205699 PMid:12154409
80. Cashen AF, Schiller GJ, O'Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol2010;28:556-61. http://dx.doi.org/10.1200/JCO.2009.23.9178 PMid:20026803
81. Blum W, Garzon R, Klisovic RB et al. Clinical response and miR-29b predictive significance in older patients treated with a 10 day schedule of decitabine. Proc. Natl Acad. Sci. 2010; 107, 7473-78 http://dx.doi.org/10.1073/pnas.1002650107 PMid:20368434 PMCid:2867720
82. Kantarjian HM, Thomas XG., Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukaemia. J Clin Oncol 2012; 30:2670-77 http://dx.doi.org/10.1200/JCO.2011.38.9429 PMid:22689805
83. Blum W, Klisovic RB, Hackanson B et al. Phase 1 study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J. Clin. Oncol. 2007; 25, 3884-91. http://dx.doi.org/10.1200/JCO.2006.09.4169 PMid:17679729
84. Kirshbaum M, Gojo I, Goldber SL et al. Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a Phase 1 dose-escalation study. Blood 2009;114, Abs824